This week, we dissect the SFDA's new, game-changing guidance on post-market surveillance for AI medical devices in Saudi Arabia. The Kingdom has raised the bar for compliance, introducing stringent new rules that require both continuous real-world data reporting and the hiring of a local, certified clinical data scientist.

This move presents a significant operational and financial challenge for international MedTech companies. We explore a real-world case of a German AI firm whose entire product launch in Riyadh was stalled by this unexpected mandate, forcing them to rethink their budget, timeline, and local strategy. This episode is a must-listen for anyone operating in or considering entry into the Saudi market.

Key Takeaways for This Episode:

- What are the two critical requirements of the SFDA's new AI surveillance guidance?

- How does the mandatory local data scientist role impact your launch budget and timeline?

- What are the hidden costs associated with the new biannual real-world data reporting?

- Is your current post-market surveillance plan now obsolete in Saudi Arabia?

- How can you find and validate an SFDA-certified expert locally?

- Does this signal a new trend towards data localization across the GCC?

- What steps should you take right now if your AI device is already on the Saudi market?

At Pure Global, we offer end-to-end regulatory consulting to help MedTech companies navigate complex landscapes like Saudi Arabia. From acting as your local representative to developing robust regulatory and data strategies, we streamline your market access. Contact us at [email protected] or visit us at https://pureglobal.com to learn more.